Next-generation drug delivery targets early-morning release

Highland Therapeutics’ novel drug delivery platform is designed to offer control over the timing of drug release and the duration of therapeutic exposure, enabling dosing at night for treatment effect starting the moment the patient wakes and lasting throughout the day. To download the full article, please sign in.

Like Comment
Page of
Go to the profile of Highland Therapeutics

Highland Therapeutics

Highland Therapeutics is an emerging pharmaceutical company that, through its wholly owned subsidiary Ironshore Pharmaceuticals & Development, Inc., is leveraging its proprietary drug delivery technology, DELEXIS®, to optimize the delivery of previously approved drugs. The Company's lead product candidates, HLD-200 (methylphenidate) and HLD-100 (amphetamine), are novel next-generation formulations of the psychostimulants commonly used in the treatment of attention-deficit/hyperactivity disorder (ADHD). Both are being investigated for the use in children and adolescents diagnosed with ADHD to address a prevalent unmet medical need – inadequate control of symptoms and functioning during the early morning routine. In addition to addressing these significant challenges during the morning routine, our products are designed to provide persistent and continuous coverage that lasts well into the early evening.

No comments yet.